share_log

Redhill Biopharma | 424B3: Prospectus

Redhill Biopharma | 424B3: Prospectus

Redhill Biopharma | 424B3:募資說明書
美股SEC公告 ·  08/13 13:42

Moomoo AI 已提取核心訊息

RedHill Biopharma Ltd., an Israeli-incorporated company, has announced a significant change to its American Depositary Receipt (ADR) program. Effective August 20, 2024, the ratio of ordinary shares per ADR will change from four hundred shares to ten thousand shares. This adjustment was filed under Rule 424(b)(3) with the file number 333-268713. The Bank of New York Mellon serves as the depositary for RedHill's ADRs, which are traded on the US stock market. The deposit agreement, initially dated December 26, 2012, outlines the rights and obligations of the ADR owners and the depositary. The agreement also details the process for surrendering ADRs, transferring, splitting, and combining receipts, as well as the liability of owners for taxes and the deposit of shares. RedHill Biopharma has made this strategic move to reflect changes in their capital structure and to align with market practices. The company remains subject to the periodic reporting requirements of the Securities Exchange Act of 1934 and files reports with the SEC, which are available for public inspection.
RedHill Biopharma Ltd., an Israeli-incorporated company, has announced a significant change to its American Depositary Receipt (ADR) program. Effective August 20, 2024, the ratio of ordinary shares per ADR will change from four hundred shares to ten thousand shares. This adjustment was filed under Rule 424(b)(3) with the file number 333-268713. The Bank of New York Mellon serves as the depositary for RedHill's ADRs, which are traded on the US stock market. The deposit agreement, initially dated December 26, 2012, outlines the rights and obligations of the ADR owners and the depositary. The agreement also details the process for surrendering ADRs, transferring, splitting, and combining receipts, as well as the liability of owners for taxes and the deposit of shares. RedHill Biopharma has made this strategic move to reflect changes in their capital structure and to align with market practices. The company remains subject to the periodic reporting requirements of the Securities Exchange Act of 1934 and files reports with the SEC, which are available for public inspection.
以色列註冊的redhill biopharma有限公司宣佈了其美國存託憑證(ADR)計劃的重大變革。自2024年8月20日起,每股普通股對ADR的比率將從400股變爲1萬股。此調整根據424(b)(3)條款的文件號爲333-268713進行。紐約梅隆銀行擔任redhill的ADR存託人,這些ADR在美國股票市場上交易。起初於2012年12月26日簽署的存託協議概述了ADR所有者和存託人的權利和義務。該協議還詳細介紹了交出ADR、轉讓、拆分和合並收據的程序,以及所有者應納稅款的責任和股票的存入。redhill biopharma採取這一戰略性舉措,以反映其資本結構的變化,並與市場慣例保持一致。該公司仍受到1934年證券交易法的定期報告要求,並向證券交易委員會提交報告,供公衆檢查。
以色列註冊的redhill biopharma有限公司宣佈了其美國存託憑證(ADR)計劃的重大變革。自2024年8月20日起,每股普通股對ADR的比率將從400股變爲1萬股。此調整根據424(b)(3)條款的文件號爲333-268713進行。紐約梅隆銀行擔任redhill的ADR存託人,這些ADR在美國股票市場上交易。起初於2012年12月26日簽署的存託協議概述了ADR所有者和存託人的權利和義務。該協議還詳細介紹了交出ADR、轉讓、拆分和合並收據的程序,以及所有者應納稅款的責任和股票的存入。redhill biopharma採取這一戰略性舉措,以反映其資本結構的變化,並與市場慣例保持一致。該公司仍受到1934年證券交易法的定期報告要求,並向證券交易委員會提交報告,供公衆檢查。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息